triumph-1 retatrutide trial results: Retatrutide, the triple agonist. Significant weight loss ( 28.3% average loss at 80 weeks). It has potential to transform obesity treatment with results comparable to… Retatrutide Delivers Bariatric-Level Weight Loss

In this retrospective cohort study, adults (1889 years) undergoing outpatient esophagogastroduodenoscopy or colonoscopy within the HCA Healthcare network from 1 July 2021 to 31 March 2024 were identified

doi:10.1016/0092-8674(90)90439-l

Additionally, patient preference for medications with dual benefits of glucose control and weight management is strengthening demand for GLP-1 therapies across global healthcare systems

Results were that incidence of biliary disease, i.e., conditions that effect the gallbladder/bile ducts, (per 1,000 person-years) was 11.7 for semaglutide, 18.6 for liraglutide (another GLP-1 agonist), and 12.6 for bupropion-naltrexone and 4.6, 7.9 and 1.0, respectively, for pancreatitis

& Pathania, R

The essential components of these therapies include prefilled pens, cartridges and autoinjectors